BLACK WEEKSFlakoni −15% · komplekti −10% · pārējais −5%ar koduBezmaksas piegāde Vācijā no €200

Šī lapa ir tulkota automātiski un var saturēt kļūdas. Vai latviešu valoda ir jūsu dzimtā valoda? Mēs labprāt saņemsim jūsu atsauksmes un labojumus.Sūtīt atsauksmi

The Peptide Desk The Peptide Desk

Šī informācija ir paredzēta tikai pētniecības un izglītības nolūkiem. Nav medicīnisku ieteikumu. Produkti nav apstiprināti lietošanai cilvēkiem. Ar veselību saistītos jautājumos konsultējieties ar ārstu.

Leksikons

Vardenafil (Levitra)

The highly selective PDE-5 inhibitor between sildenafil and tadalafil: onset from about 10 minutes, a 4 to 5 hour window and less blue-tinged vision.

10 min read 11 sources

Molecule model of blue and white glass spheres with a yellow atom and several rings above a white podium with a glowing light blue rim in a bright lab
Compound approved · in the US since 2003

Summary

At a glance

Sources checked on 26 Oct 2026

Earliest difference from placebo
10 minutes

stopwatch trial with 732 men, middle study dose2

Half inhibition of PDE5
0.7 nM

sildenafil 6.6 nM in the same lab, almost ten times more4

Half-life
~4 hours

peak level after 0.7 to 0.9 hours3

Improved erections
80 %

highest study dose after 12 weeks, 30 percent with placebo1

  • Vardenafil inhibits the enzyme PDE5. The messenger cGMP persists longer, with sexual arousal an erection forms more easily. Without arousal nothing happens.118
  • In a lab comparison vardenafil inhibited PDE5 at 0.7 nM, sildenafil only at 6.6 nM. Over PDE6 in the retina it was 16-fold selective, sildenafil 7.4-fold.4
  • The peak level comes in under an hour, the half-life is about 4 hours. In the stopwatch trial the difference from placebo showed from 10 minutes.32
  • In diabetes and after prostate removal too, clearly more men reported improved erections than with placebo. The most common side effects are headache and flushing, combined with nitrates it is dangerous.678
  • Vardenafil has been approved in the US since 2003. Everything here is the state of research, not a recommendation.9
Profils

Updated October 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~4 hours

Half-life ~4 hours
After 8 hours: 25 %
Hour 4 · 50 %Hour 8 · 25 %Hour 12 · 12.5 %Hour 20 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Class
PDE-5 inhibitor

Levitra, Vivanza

Use
Oral

on demand, about 30 to 60 minutes before, at most once in 24 hours

Onset
Peak levels after about 1 hour

success possible from 10 minutes

Half-life
About 4 hours
Window
Around 4 to 5 hours
Status
Clinically approved

EU and FDA 2003

Sizes
10 to 20 mg

2 sizes in the shop

Saturs 15 sections
  1. Īsumā
  2. What is vardenafil?
  3. How it works
  4. Pharmacokinetics: in fast, out within hours
  5. Use and dosing
  6. Vardenafil, sildenafil or tadalafil?
  7. What the research shows
  8. Pētījumu stāvoklis
  9. Side effects
  10. Safety and interactions
  11. Storage
  12. Saistītie savienojumi
  13. BUJ
  14. Terminu vārdnīca
  15. Avoti

What is vardenafil?

Vardenafil is the third of the classic PDE-5 inhibitors. Bayer brought it to market in 2003 as Levitra. In parts of Europe it is sold as Vivanza. Chemically it is a close cousin of sildenafil, an imidazotriazinone rather than a pyrazolopyrimidinone. That small change in the ring system is what makes it markedly more potent at the target enzyme.

In profile it sits between the two better-known members of the class: absorbed as quickly as sildenafil, with a half-life of around 4 hours and a working window of roughly 4 to 5 hours, nowhere near the 36 hours of tadalafil. It is taken on demand as a tablet, about half an hour to an hour before. Besides the film-coated tablet there is a 10mg orodispersible tablet (Staxyn), which according to Sanford (Drugs 2012) consistently delivers higher exposure and is therefore not interchangeable one to one. You can order vardenafil as film-coated tablets of 20mg, 10 per blister.

This information is for research and educational purposes only. No medical advice.

How it works

During sexual arousal, nerve endings in the erectile tissue release nitric oxide. That raises the messenger cGMP inside the smooth muscle cells, the muscle relaxes, the arteries widen and the corpora cavernosa fill with blood. The swelling tissue presses the draining veins against the firm outer sheath (tunica albuginea), outflow is throttled and the erection holds. The enzyme phosphodiesterase type 5 breaks cGMP down again and ends the signal. Vardenafil blocks PDE5, so the messenger survives longer. Without arousal the chain never starts, which is why nothing happens without stimulation.

What sets vardenafil apart from sildenafil is potency at the enzyme. Saenz de Tejada and colleagues (International Journal of Impotence Research 2001) compared the two head to head: vardenafil inhibits PDE5 with an IC50 of 0.7 nM, sildenafil needs 6.6 nM, almost ten times as much. Against PDE6, the related enzyme in the rods and cones of the retina, vardenafil is 16-fold selective versus 7.4-fold for sildenafil. Against PDE1 in heart and vessels it is 257-fold versus 60-fold. In human erectile tissue vardenafil enhanced NO-mediated relaxation from 3 nM, sildenafil from 10 nM. The higher potency explains why the doses of 5 to 20mg are so much smaller than sildenafil's. The better PDE6 selectivity explains why the blue tinge in vision is reported less often.

Where it acts

Where vardenafil acted in studies

Tap a point or a card. Colour = PDE5, grey = observed in studies.

  1. Erectile tissue

    Inhibits PDE5, cGMP persists, erection with arousal easier11

    PDE5
  2. Retina

    PDE6 inhibited 16-fold more weakly than PDE5, sildenafil 7.4-fold4

    Observed in trials
  3. Blood pressure

    Enhances the blood pressure drop from nitrates, no safe interval known8

    Observed in trials
  4. Liver

    Breakdown via CYP3A4, ritonavir raised total exposure 49-fold8

    Observed in trials
  5. Heart

    Slight QT prolongation, it adds up with other QT drugs8

    Observed in trials

Targets in the ChEMBL database11

Compound CHEMBL1520 (Hydrochlorid CHEMBL1339): one recorded mechanism, Inhibitor.

Phosphodiesterase 5A
Gene
PDE5A
UniProt
O76074
ChEMBL
CHEMBL1827
Action
Inhibitor
Glass blood vessel with two pockets in its wall holding blue molecules, a turquoise glow inside
Vardenafil blocks PDE5, the vessels stay wide for longer. Symbolic image.

Pharmacokinetics: in fast, out within hours

Klotz and colleagues (World Journal of Urology 2001) measured median peak levels 0.9 and 0.7 hours after 10 and 20mg, after which concentrations fell with a terminal half-life of 4.2 and 3.9 hours. Exposure rose in proportion to dose, so 20mg gives roughly twice the level of 10mg. On RigiScan a single 10mg dose extended the time above 60 percent rigidity by about 24 minutes over placebo, 20mg by 29 to 37 minutes.

Food matters, but less than often assumed. Rajagopalan and colleagues (Journal of Clinical Pharmacology 2003) gave 20mg fasted and after a high-fat breakfast: the peak moved from 1 to 2 hours and dropped by just under a fifth, total exposure stayed the same. A typical moderate-fat evening meal changed practically nothing. So if you want the fast window, do not take vardenafil straight after a heavy meal, but you do not need to be fasted either.

According to the prescribing information vardenafil is cleared mainly by CYP3A4, with minor contributions from CYP3A5 and CYP2C enzymes. That is where interactions arise: strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir or clarithromycin raise levels several-fold. Grapefruit juice pushes in the same direction. More under safety.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts
White folding box with the TPD logo next to a blister of ten round white tablets, two loose tablets in front on a bright lab bench
Tablets in a blister. Symbolic image.

Vardenafil, sildenafil or tadalafil?

The three classic PDE-5 inhibitors share the mechanism and differ in time profile and off-targets:

  • Vardenafil works from about 10 minutes, peaks at around an hour, window about 4 to 5 hours. The most potent of the three at the enzyme, more PDE6-selective than sildenafil, so visual disturbances are rarer. Doses 5 to 20mg.
  • Sildenafil is similarly fast and similarly long (4 to 6 hours) but reacts more to fatty food and brings the blue tinge in vision more often. Doses 25 to 100mg.
  • Tadalafil lasts up to 36 hours on a 17.5 hour half-life and can be dosed low daily, at the price of the typical back and muscle aches, probably via PDE11. Doses 2.5 to 20mg.

On raw efficacy, network meta-analyses disagree on the ranking. Yuan and colleagues (European Urology 2013) saw tadalafil and vardenafil as the most effective agents across 118 trials, with no major difference in safety. Chen and colleagues (European Urology 2015) instead compared starting doses: sildenafil 50mg was the most effective but also had the most adverse events, tadalafil 10mg offered the best trade-off. Vardenafil 10mg sat at sildenafil's level for adverse events but below it for global efficacy. The practical reading: vardenafil is the pick for a short, plannable window when sildenafil does not suit because of visual effects or food sensitivity. Which one fits best remains individual.

Comparison

Four PDE-5 inhibitors side by side

All inhibit the same enzyme and differ in their time course, as stated in the TPD lexicon. Tap a card to open its entry.

Simplified: in the network meta-analysis of 82 trials vardenafil at its starting dose had about as many side effects as sildenafil but a clearly lower overall efficacy. Direct comparison trials are rare. 5

What the research shows

Vardenafil is well evidenced by several large placebo-controlled trials. In the first at-home study by Porst and colleagues (2001), 601 men with mild to severe erectile dysfunction took placebo or 5, 10 or 20mg on demand for 12 weeks. All three doses improved every IIEF domain significantly, 71 to 75 percent of intercourse attempts succeeded. On 20mg, 80 percent reported improved erections versus 30 percent on placebo. The 26-week fixed-dose trial summarised by Ormrod and colleagues (Drugs and Aging 2002) reached 85 versus 28 percent in 736 men.

The effect holds in hard populations too. Goldstein and colleagues (Diabetes Care 2003) randomised 452 men with diabetes: after 12 weeks, 57 percent on 10mg and 72 percent on 20mg reported improved erections versus 13 percent on placebo, at every level of HbA1c. Brock and colleagues (Journal of Urology 2003) studied 440 men after nerve-sparing radical prostatectomy, 70 percent of them with severe dysfunction: 59 percent on 10mg and 65 percent on 20mg reported improvement versus 12.5 percent on placebo.

Montorsi and colleagues (Journal of Sexual Medicine 2004) timed onset with a stopwatch in 732 men, with vardenafil significantly ahead of placebo from 10 minutes. Klotz and colleagues (World Journal of Urology 2001) supplied the pharmacokinetic cornerstones, peak under an hour and a half-life around 4 hours. What is missing: no PDE-5 inhibitor has large long-term trials with hard cardiovascular endpoints. The comparisons between agents are mostly indirect. The linked papers are in the source block below.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Share with improved erections167

Global question after 12 weeks, three placebo-controlled trials

Mixed causes1 601 men
Placebo 30.0%
Highest study dose 80.0%
With diabetes6 452 men
Placebo 13.0%
Middle study dose 57.0%
Highest study dose 72.0%
After prostate removal7 440 men, 70 percent severe dysfunction
Placebo 12.5%
Middle study dose 59.4%
Highest study dose 65.2%

In the first at-home trial 71 to 75 percent of intercourse attempts succeeded at all three doses, the abstract gives no share of improved erections for the middle and lowest dose.

Successful intercourse within 25 minutes2

732 men, at least once in the first four doses

Stopwatch trial2
Placebo 26%
Middle study dose 50%
Highest study dose 53%

Significant from 10 minutes at the middle and from 11 minutes at the highest dose. No one stopped because of side effects.

Distance to related enzymes4

How much more weakly the enzyme is inhibited than PDE5, measured directly against sildenafil

PDE6 (retina)4
Sildenafil (comparison) 7.4-fold
Vardenafil 16.0-fold
PDE1 (heart and vessels)4
Sildenafil (comparison) 60.0-fold
Vardenafil 257.0-fold

Over PDE2, PDE3 and PDE4 inhibition was above 1,000 nM. In human erectile tissue vardenafil enhanced relaxation from 3 nM, sildenafil from 10 nM.

Curved blood vessel with red blood cells and fine branches on glass supports, racks of sample tubes beside it in a bright lab
Large placebo trials, also in diabetes and after prostate removal. Symbolic image.

Research status

Where the research stands

Vardenafil has been approved in the US since 2003. ClinicalTrials.gov lists 83 trials with vardenafil. The early trials in diabetes and after prostate removal are older than the registry. Shown is a selection of completed phase 3 trials. As of 26 Oct 2026. 10

  1. Preclinical Selectivity across phosphodiesterases, erectile tissue and erection in rabbits
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 8 trials, 8 completed
  5. Approval in the US since 2003
3,834 participants in phase 3 Approved: in the US since August 2003 (Drugs@FDA, NDA 021400), ChEMBL lists vardenafil with phase 4 as the highest phase.9
Show all 8 phase 3 trials on a timelineHide timeline 8 completed 0 running 1 with results
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026.

Side effects

  • Headache: the most common effect, 7 to 15 percent in the first at-home study and dose-dependent (Montorsi: 7 percent on 10mg, 12 percent on 20mg, 1 percent on placebo).
  • Flushing: facial redness and warmth in about 6 to 11 percent, also dose-dependent.
  • Stuffy nose (rhinitis) and heartburn (dyspepsia): each up to about 7 percent (rhinitis up to 10 percent in diabetics), mild to moderate and transient. Sinusitis is also reported in the registration trials.
  • Vision: the blue tinge is rarer than with sildenafil thanks to the higher PDE6 selectivity; Keating and Scott (Drugs 2003) report no abnormal colour vision at 5 to 20mg in the registration trials. The class warning still applies: a sudden loss of vision in one or both eyes is a reason to stop and an emergency (non-arteritic anterior ischaemic optic neuropathy, rare).
  • Hearing: sudden hearing loss or tinnitus are described as rare class effects and also need checking.
  • Priapism: an erection lasting more than four hours is a urological emergency; untreated, permanent damage to the erectile tissue can follow.
  • QT interval: Morganroth and colleagues (American Journal of Cardiology 2004) measured a placebo-corrected QTc prolongation of about 8 ms on 10mg, about 6 ms on sildenafil 50mg, with a shallow dose-response and no clinical relevance in healthy men. Anyone on class IA or III antiarrhythmics or with congenital long QT syndrome should avoid vardenafil per the prescribing information.

Tolerability

Side effects compared with placebo

Out of 100 participants per group, how many had the event.

4 of 100 Placebo
15 of 100 Vardenafil
Event PlaceboVardenafil
Headache8 4%15%
Flushing8 1%11%
Rhinitis8 3%9%
Dyspepsia8 1%4%
Sinusitis8 1%3%

Values from the US label, all doses combined. Headache, flushing, dyspepsia, nausea and rhinitis rose with the dose. 3.4 percent stopped because of side effects, 1.1 percent with placebo.8

Safety and interactions

The most important point of the whole class: vardenafil must never be combined with nitrates. That covers heart nitrates such as nitroglycerin, isosorbide dinitrate and isosorbide mononitrate, but also amyl nitrite and the alkyl nitrites sold as poppers. Nitrates supply nitric oxide while vardenafil protects the resulting cGMP from breakdown. Together they can crash blood pressure to life-threatening levels. In healthy volunteers, vardenafil 20mg still amplified the blood pressure drop from nitroglycerin 1 and 4 hours after dosing, but no longer at 24 hours. Even so, the prescribing information defines no safe interval, the combination stays off the table. The same applies to guanylate cyclase stimulators such as riociguat.

Alpha-blockers (tamsulosin, alfuzosin, doxazosin) also lower blood pressure and the effects add up. The prescribing information requires a stably adjusted alpha-blocker and a 5mg start. CYP3A4 inhibitors raise vardenafil levels several-fold (ritonavir by 49-fold per the US label): the EU SmPC rules out ritonavir and indinavir entirely and advises against ketoconazole and itraconazole, while erythromycin and clarithromycin carry the 5mg cap from the dosing section. Grapefruit juice works in the same direction. Alcohol in larger amounts worsens the erection and amplifies the drop in blood pressure and dizziness.

Sexual activity is a load on the circulation. With unstable angina, a heart attack or stroke within the last six months, severe heart failure, very low or uncontrolled high blood pressure, the question is not the drug but the capacity to exert. Anyone with pre-existing conditions or on medication clears it with a doctor first. This is not an area for experiments.

Storage

Store the film-coated tablets dry, at room temperature and protected from light, out of reach of children. Keep the blister closed and open it only for use. Do not leave a halved tablet lying around for long. Mind the expiry date.

Three white tablet bottles on a bright shelf next to a folded light blue towel
Dry, at room temperature and away from light, keep the blister closed. Symbolic image.

Related

Related compounds

Same targets or a different path: all in the TPD lexicon.

FAQ

Common questions about Vardenafil (Levitra)

Short answers, each backed by the sources below.

How does vardenafil work?

With arousal nerves in the erectile tissue release nitric oxide, the messenger cGMP rises and the vessels widen. PDE5 breaks cGMP down again. Vardenafil inhibits PDE5 and the signal lasts longer. Without sexual stimulation the chain does not start.114

How fast does it work and for how long?

The peak level came after 0.7 to 0.9 hours, the half-life was about 4 hours. In the stopwatch trial with 732 men the difference from placebo was significant from 10 to 11 minutes. Within 25 minutes intercourse succeeded in 50 to 53 percent, with placebo in 26 percent.32

What sets vardenafil apart from sildenafil?

In a direct lab comparison vardenafil inhibited PDE5 at 0.7 nM, sildenafil at 6.6 nM. Over PDE6 in the retina the gap was 16 versus 7.4, over PDE1 257 versus 60. That is why the doses are smaller. In the network meta-analysis the starting dose of vardenafil was weaker overall than that of sildenafil.45

Does it also work in diabetes or after prostate surgery?

Yes, at a lower level. In 452 men with diabetes 57 and 72 percent at the middle and highest dose reported improved erections, 13 percent with placebo, at every HbA1c level. After nerve-sparing prostate removal (440 men, 70 percent severe dysfunction) it was 59 and 65 versus 12.5 percent.67

Is vardenafil approved?

Yes. In the US since August 2003, ChEMBL lists it with phase 4 as the highest phase. ClinicalTrials.gov lists 83 trials (as of 26 October 2026). Everything here is the state of research, not a recommendation.91110

Why never with nitrates?

PDE-5 inhibitors enhance the blood pressure drop caused by nitrates. The US label knows no safe interval between vardenafil and a nitrate, the combination is ruled out. That also applies to other nitric oxide donors. Strong CYP3A4 inhibitors raise the level sharply, ritonavir the total exposure 49-fold.8

Which side effects are common?

In the pooled trials headache in 15 versus 4 percent, flushing in 11 versus 1 percent and rhinitis in 9 versus 3 percent. Several of them rose with the dose. For the whole class: sudden loss of vision or hearing and an erection lasting over four hours are an emergency.8

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

cGMP
A messenger inside the cell that relaxes vessel muscle. PDE5 breaks it down.
CYP3A4
Liver enzyme that breaks down vardenafil. If something inhibits it, the level rises sharply.
Global assessment question (GAQ)
Question at the end of a trial: has the treatment improved your erections?
Half-life
The time until the amount in the blood has fallen by half.
IC50
The concentration at which a compound inhibits an enzyme by half. The smaller, the stronger.
Nitrates
Vessel-widening drugs such as nitroglycerin and the alkyl nitrites sold as poppers.
Nitric oxide
A gaseous messenger (NO) that relaxes smooth muscle and widens vessels.
PDE-5 inhibitor
A class of compounds that slows the enzyme PDE5. It includes vardenafil, sildenafil, tadalafil and avanafil.
PDE5
Enzyme in the erectile tissue that breaks down cGMP and so ends the erection.
PDE6
A related enzyme in the retina. Its inhibition explains the blue tinge in vision.
QT interval
A section of the ECG. If it is prolonged, the risk of dangerous heart rhythm disorders rises.
Selectivity
How strongly a compound prefers its target. High selectivity means little effect on other enzymes.

Pierādījumi

Avoti

Show all 11 sourcesHide sources 7 Studies1 Trial registry3 Database checked 26 Oct 2026

Studies

  1. First at-home trial with 601 men over 12 weeks

    Porst et al., International Journal of Impotence Research, 2001

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Stopwatch trial: onset in 732 men

    Montorsi et al., Journal of Sexual Medicine, 2004

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. RigiScan and pharmacokinetics in 21 men

    Klotz et al., World Journal of Urology, 2001

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Selectivity and potency in direct comparison with sildenafil

    Saenz de Tejada et al., International Journal of Impotence Research, 2001

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Network meta-analysis: efficacy versus side effects of PDE-5 inhibitors

    Chen et al., European Urology, 2015

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Vardenafil in 452 men with diabetes

    Goldstein et al., Diabetes Care, 2003

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. Vardenafil after nerve-sparing prostate removal

    Brock et al., Journal of Urology, 2003

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials on vardenafil on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. US prescribing information for vardenafil (side effects, interactions)

    DailyMed, U.S. National Library of Medicine (Stand 15.07.2026)

    Checked 26 Oct 2026 via openFDA Label API, DailyMed
  2. First approval in the US (NDA 021400, 2003)

    Drugs@FDA, U.S. Food and Drug Administration

    Checked 26 Oct 2026 via Drugs@FDA, openFDA
  3. Mechanism in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL1520, Hydrochlorid CHEMBL1339)

    Checked 26 Oct 2026 via ChEMBL

Veikalā

Vardenafil (Levitra) in the catalog

Izmēri, cenas un piegādes laiki ir norādīti produkta lapā.

Uz produktu